Abstract

Familial hypercholesterolemia (FH) is a genetic disorder, characterized by high blood cholesterol levels, particularly – very high low-density lipoprotein (LDL) levels, which leads to the development of cardiovascular disease at a young age. Heterozygous FH is diagnosed in the general population in most countries in one of 500 people. Certain phenotypic manifestations of this disease have been identified, namely: tendon xanthomas, lipid arch of the cornea and xanthelasma. Patients with FH are prone to early development of atherosclerosis and clinically manifest forms of cardiovascular diseases, in particular ischemic heart disease. A direct correlation has been established between morbidity, mortality from coronary heart disease and blood cholesterol level. It has also been proven that hypercholesterolemia is the main risk factor for the development of atherosclerosis and its complications. Early diagnosis and modern lipid-lowering therapy play an important role for patients with signs of hereditary lipid metabolism disorders. Patients with heterozygous FH are usually treated by statins, which act by inhibiting an enzyme in the liver. Statins are effective in lowering total cholesterol and LDL levels. Sometimes other drugs are additionally prescribed. The diagnosis of this pathology requires a genetic consultation. All patients with FH require lifelong pharmacological therapy. The use of statins leads to a decrease in coronary mortality by 25–40%, and decrease in the risk of ischemic events – by 26–30%. An observational study of a large British registry noted that mortality in patients with FH began to decline slightly from the early 90s of the XX century, when statins were started to use in treatment. The article presents a clinical case of ischemic heart disease in heterozygous FH patent, considers diagnostic criteria and modern approaches to the management of patients with hereditary disorders of lipid metabolism.

Highlights

  • Familial hypercholesterolemia (FH) is a genetic disorder, characterized by high blood cholesterol levels, – very high low-density lipoprotein (LDL) levels, which leads to the development of cardiovascular disease at a young age

  • що гіперхолестеринемія є головним чинником ризику розвитку атеросклерозу та його ускладнень

  • Heterozygous FH is diagnosed in the general population in most countries

Read more

Summary

Introduction

Familial hypercholesterolemia (FH) is a genetic disorder, characterized by high blood cholesterol levels, – very high low-density lipoprotein (LDL) levels, which leads to the development of cardiovascular disease at a young age. В статье представлен клинический случай ишемической болезни сердца и гетерозиготной СХГ, рассмотрены диагностические критерии и современные подходы к ведению пациентов с наследственными нарушениями липидного обмена. Маніфестує СГХС зазвичай з розвитку субклінічного атеросклерозу, що в подальшому призводить до швидкого виникнення та прогресування ІХС. За даними Британського реєстру Саймона Брума, хворі на СГХС віком 20–39 років мають 100-кратне збільшення ризику смерті від коронарних ускладнень і 10-кратний ризик загальної смертності [7, 10].

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.